Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.59 |
| ▸ | RELA | Q04206 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068644 | 0.92 | MAPK1 (0.56) | MAPK1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL9942331 | 0.85 | NPC1 (0.73) | MAPK1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL19794465 | 0.79 | NPC1 (0.64) | MAPK1NFKB1RAB9ANFKB2RELA | |
| SCHEMBL115115 | 0.78 | ALDH1A1 (1.00) | MAPK1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL30451936 | 0.78 | ALDH1A1 (1.00) | MAPK1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL23239880 | 0.78 | MAPK1 (0.58) | MAPK1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL29237525 | 0.78 | MAPK1 (0.71) | MAPK1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL15916322 | 0.78 | ALDH1A1 (0.52) | MAPK1ALDH1A1 | |
| SCHEMBL24809560 | 0.78 | ALDH1A1 (0.52) | MAPK1ALDH1A1NFKB1RAB9ANFKB2 | |
| SCHEMBL18015263 | 0.77 | MAPK1 (0.57) | MAPK1ALDH1A1NFKB1RAB9ANFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20210111345-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2021-04-15 | — | — | US | disclosed |
| WO-2019179909-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210111345-A1 | METAL COMPLEXES | NCLN, BICRA, AP3M1 | MAPK1 4348/4885ALDH1A1 4579/4885NFKB1 835/4885 |
| US-11917903-B2 | Metal complexes | NCLN, BICRA, AP3M1 | MAPK1 4348/4885ALDH1A1 4579/4885NFKB1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.